Home > Healthcare > Biotechnology > Biopharma > Antibody Therapy Market

Antibody Therapy Market - By Type [Monoclonal Antibodies (mAbs) {Oncology, Autoimmune Disease, Infectious Disease}, Antibody-drug Conjugates (ADCs)], By End-use (Hospitals, Specialty Centers) – Global Forecast, 2023 – 2032

  • Report ID: GMI5195
  • Published Date: Dec 2023
  • Report Format: PDF

Antibody Therapy Market Size

Antibody Therapy Market size accounted for USD 214.7 billion in 2022 and is projected to expand at 11.8% CAGR from 2023 to 2032. The industry is experiencing exponential growth from the last few years as new therapies and drugs have been approved for the treatment of diseases. To date, the Food and Drug Administration (FDA) has approved more than 100 antibody products and every year around a fifth of new drug approvals are of biologics. The presence of a healthy antibody therapy pipeline creates a high potential for the company to attain larger market revenue.

Antibody Therapy Market

Antibody therapy is a targeted therapeutic intervention comprising concentrated or monoclonal antibody used to manage diseases such as cancer/oncology, infectious diseases and autoimmune diseases among other diseases. These therapeutic antibodies bind to specific molecules on the surface of cells, triggering immune responses that help eliminate or inhibit the growth of abnormal cells. This precise targeting makes antibody therapy a promising approach for treating various diseases, offering a tailored and effective strategy in the field of medical intervention and personalized medicine.

COVID-19 Impact

While the influence of COVID-19 had been mostly negative in several areas, the antibody therapy industry gained considerable momentum due to a spike in demand for the treatment development of COVID-19. Several companies commenced their R&D at a faster pace for the development of diagnostic and treatment related to COVID. The FDA and other organizations of various countries gave emergency use authorizations (EUAs) for the use of anti-SARS-CoV-2 mAb and other antibody therapy for the treatment of mild to moderate COVID-19 infection. Hence, COVID-19 showed a positive effect on the market of antibody therapy in 2020.

Antibody Therapy Market Trends

  • The government and key market players have significantly increased R&D expenditure due to the high demand for antibody therapy in the market. Governmental support for the launch of novel treatment is expected to contribute to strong market growth. In September 2021, Amgen received FDA approval for its Repatha (evolocumab) for the treatment of heterozygous familial hypercholesterolemia (HeFH) patients aged 10 years and older. This approval will benefit the patients suffering from HeFH.
  • Moreover, growing regulatory approvals and the introduction of new drugs further contribute to this positive trend. For instance, between April and June 2023, approvals included antibody-drug conjugates for diverse cancers, bispecific T-cell engagers targeting B-cell malignancies, with other applications. As the global cancer risk escalates, there is an increased demand for clinically secure treatments, favouring antibodies.

Antibody Therapy Market Analysis

Antibody Therapy Market Size, By Type, 2021 - 2032 (USD Billion)

The market based on type is segmented into monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The monoclonal antibodies (mAbs) segment is further split into oncology, autoimmune diseases, infectious diseases, and other monoclonal antibodies. The mAbs segment is expected to exhibit 11.7% CAGR during the forecast period.

  • The segment dominance is majorly attributed to the increasing application of mAbs for the chronic diseases such as cancer, infection, genetic diseases, and others.
  • mAbs as biologic products obtains several immune-mediated reactions and responses which increases the efficiency of the therapy.
  • Also, mAbs are synthesized using recombinant biotechnology and progress in protein engineering, recombinant DNA technology, and various other platforms for generating different types of antibodies based on novel strategies, resulting in future segment market growth of antibody therapy over forecast period.
Antibody Therapy Market Share, By End-use (2022)

The antibody therapy market based on end-use is categorized into hospitals, specialty centers, and other end-users. The hospitals segment held the major share of 47.6% in 2022.

  • The dominance of the hospital segment in the market is attributed to its role as a primary healthcare provider for severe and chronic diseases. Hospitals are equipped with specialized infrastructure, skilled personnel, and advanced technology required for administering and monitoring antibody therapies.
  • Additionally, hospitals serve as hubs for critical care and emergency situations, making them epicenter in the treatment of disease conditions. This concentration ensures efficient delivery and management of these therapies, reinforcing the hospitals' pivotal role in the market.
U.S. Antibody Therapy Market Size, 2020- 2032 (USD Billion)

The North America antibody therapy market is expected surpass the revenue USD 284.0 billion by 2032.

  • The region robust regulatory framework, rising investment in novel antibody therapy development by key players are few of the factors predicted to propel regional market growth. For instance, in August 2023, BARDA has partnered with Regeneron under 'Project NextGen' to aid the development and regulatory process of an advanced COVID-19 monoclonal antibody therapy, aiming to prevent SARS-CoV-2 infection. The collaboration involves clinical development and manufacturing support to accelerate the progress of innovative COVID-19 vaccines and treatment.
  • Further, the presence of key market players, extensive healthcare facilities, and a proactive approach to adopting innovative treatments further solidify North America's prominence in the antibody therapy sector.

Antibody Therapy Market Share

The key players are actively engaged in strategic collaborations, product launches, and acquisitions to strengthen their market position. The market also witnesses a surge in biosimilar competition, intensifying rivalry. Strong R&D initiatives, coupled with regulatory approvals, show the dynamic competition, fostering advancements in antibody therapies and shaping the market's evolving competitive landscape.

Market players operating in the antibody therapy is as mentioned below:

  • F. Hoffmann-La Roche Ltd.
  • AbbVie, Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • Seagen
  • Merck & Co., Inc.
  • Regeneron Pharmaceuticals Inc.
  • Novartis AG
  • AstraZeneca
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • Takeda Pharmaceutical Company Ltd.

Antibody Therapy Industry News:

  • In October 2023, AbCellera has broadened its ongoing multi-target partnership with Regeneron, aiming to identify therapeutic antibodies for up to eight targets specified by Regeneron, an increase from the initial four. This extended collaboration anticipates an expansion in the production of novel therapeutic antibodies.
  • In August 2023, Tillotts Pharma and TVM Capital Life Science collaborated to establish Mage Biologics, dedicated to pioneering an innovative oral antibody therapy for ulcerative colitis. The establishment of the Mage Biologics aims in advancing humanized monoclonal antibody (mAb) for optimal potency and effectiveness, thereby strengthening its market position.

The global antibody therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Type 2018 – 2032 (USD Million)

  • Monoclonal antibodies (mAbs)
    • Oncology
    • Autoimmune diseases
    • Infectious diseases
    • Other monoclonal antibodies (mAbs) 
  • Antibody-drug conjugates (ADCs)

By End-use 2018 – 2032 (USD Million)

  • Hospitals
  • Specialty centers
  • Other end-users

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada 
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Singapore
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Egypt
    • Rest of Middle East & Africa


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global antibody therapy industry size accounted for USD 214.7 billion in 2022 and is expected to reach USD 638.2 billion by end of 2032, favored by the approval of new therapies and drugs for the treatment of diseases.

The hospitals segment held the major market share of 47.6% in 2022 and will continue to grow owing to its role as a primary healthcare provider for severe and chronic diseases. Hospitals have specialized infrastructure, skilled personnel, and advanced technology required for administering and monitoring antibody therapies.

North America antibody therapy market is expected surpass USD 284 billion by 2032, owing to the robust regulatory framework as well as rising investment in novel antibody therapy development by key players.

F. Hoffmann-La Roche Ltd., AbbVie, Inc., Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Seagen, Merck & Co., Inc., Regeneron Pharmaceuticals Inc., and Novartis AG among others.

Antibody Therapy Market Scope

Buy Now

Premium Report Details

  • Base Year: 2022
  • Companies covered: 13
  • Tables & Figures: 219
  • Countries covered: 24
  • Pages: 150
 Download Free Sample